The working from home revolution has the potential to annihilate the middle class’s vice-like grip on the best paid jobs
Tom Winnifrith Bearcast: Answering Malcolm's question in detail ref Optibiotix & Skinbiotherapeutics and gosh these Tories are dim
Gold – Thursday’s low to be retested but Jordan Roy-Byrne thinks it is almost time to buy. $2600 Gold by Jan 2022?
Hello, Share Testers. Let’s have a bit of fun looking at Avacta (AVCT) again. This share is like an irritable fly buzzing around my head. We all know that the company looks hugely overvalued, that is if you strip out the possibility of the company being involved in some major testing operation. Uncle Tom has famously attacked the chances of this ever happening. Yet the share price is quite resilient...
Even where the Government is testing like the blazes to cover its arse and con us into believing that its coronavirus response was sensible and proportionate, it is struggling to find cases. In the new 'hotspot' of Blackburn where there is mass testing, the cases are just 77 per 100,000. Of those found posititve, nearly all of them are asymptomatic so would not have known they had Covid had they not been tested. This testing is not saving any lives.
Our response to Coronavirus divides us ever more. I argue that wrecking the world economy will cause untold misery and was the wrong response to a virus that largely polished off fplks who were already on St Peter’s short list for a fairly imminent interview. For this I am branded “irresponsible” by one reader today while others accuse me of callously wishing to deny many more years of happy and active life to their 95 year old grandparents or parents. So what if deaths across Europe are falling to sod all, the lockdown jihadists warn of an imminent second wave. But deaths, even in the US, are falling. This pandemic is tailing off which is a problem if you are Avacta (AVCT)
Forgive me, dear readers, for returning to the matter of the great Coronavirus bubble but data came out late Thursday from the ONS which screams at you that it is about to pop.
Hello, Share Speakers. It’s a while since anyone on this amazing site, referred to Avacta (AVCT). But it still remains one of the biggest talking points in the share world. It’s one of those covid related stocks, which like most of them, goes up and down a lot every day. Uncle Tom is very bearish on Avacta, but I notice that unlike some luckless companies, it’s not being shorted too much.
With shares in Avacta (AVCT) ludicrously overvalued at 138p the company rightly fears that when the second tranche of stock from the recent placing at 120p is admitted to the AIM Casino tomorrow there will be a line of folks wanting to flip. What to do? Of course, get your evil morally bankrupt PR spinners at Yellow Jersey to issue complete non news and make it sound exciting. Heck Yellow Jersey managed to persuade suckers to pile into mega and obvious fraud Frontera (FRR) so they can push any shite uphill. For a while at least.
Hello, Share Swashers. As the page views show, interest in the Avacta (AVCT) saga remains very high among the elite group of Shareprophets subscribers. Judging by the bulletin boards on some lesser websites, interest is also keen if often laughably optimistic. Allow me to give you an update on this most volatile of virus-related plays...
I see that Barry “The Tit” Gibb at broker Turner Pope has produced a gushing note on Avacta (AVCT ) today. Maybe that will help a few more Turner Pope clients to flip the stock they got in the recent 120p placing. Or maybe The Tit just wants a distraction from wittering an about Tomco (TOM), shares in which remain suspended although it has, today, been forced to admit that its RNS that accompanied a Turner Pope placing yesterday, contained a massive porky. Back to Avacta, when your cheerleader in chief is “The Tit” you know it is right to be bearish.
Hello Share Keepers. As wise Shareprophets contributor Periotlunaire rightly observes: trading shares in Avacta Group (AVCT) is a poker game. While Uncle Tom says we should sell this small medical pioneer because the company is grossly overvalued and the current share price won’t last much longer...
When you have just raised £48 million of dumb money you cannot turn around a week later and scream SUCKERS! No. You have to pretend that the reason your shares raced away and that the fools piled in greedily is still valid. But it is not, and at some stage, Avacta (AVCT) will have to admit as much.
Hello, Share Isolators. The question of what to do with Avacta (AVCT) shares continues to be even thornier. The price exceeded 200p a week or so ago, then began a double-digit daily decline. Towards last week’s end it perked up again and at the time of writing is 157p...
Hello, Share Tasters. Once again, I’m in the unenviable position of holding loads of shares in a company that Tom finds to be overvalued. When this happens I tend to dump most of the shares, as Tom has a surgical mind and I’m an instinct man. Yes, it may be an instinct based on centuries of daily share dealing experience but you have to consider what cold analysts like Tom think too. I hold shares in Avacta (AVCT)...
A week ago, Malcolm Stacey could have sold his shares in Avacta (AVCT) at more than 200p each. In fact I think the old trading genius might just have done that. Then the company started “sounding out” investors about a fund raise and, not that anyone in London ever breaks insider dealing laws so this is a total coincidence, the shares started tumbling fast. As I write they are off by 5p at 132-5p as it has announced am up to £45 million fund raise at 120p. I don’t blame it.
Hello, Share Fielders. A few weeks ago, Uncle Tom did the sums and pronounced that the valuation of Avacta (AVCT) after some spectacular share rises was ‘bonkers.’ If it was bonkers then, it must be mega-bonkers now as the price has risen relentlessly whether the action is justified or not and is now above 200p. When I first commended it to your researches it was less than 20p, but can this potential bubble stay unpricked for a bit longer?...
Hello, Share Shifters. I find myself on the horns of a horrible dilemma. And once again, it’s due to Uncle Tom Winnifrith. He has written a couple of immaculately researched pieces on this legendary website warning that a company in my portfolio is overvalued. Indeed, he says the valuation of medical pioneer Avacta (AVCT) is 'bonkers'...
Hello, Share Takers. Uncle Tom has described the valuation of Avacta Group (AVCT) as ‘bonkers’. With his diamond record, few will quarrel with that. Therefore, long-term players should probably avoid this stock. But what about opportunistic momentum investors?...
Hello Share Plodders. It’s all beginning to look more optimistic don’t you think? A human trial for a vaccine started at Oxford University. Many more tests being rolled out. The number of sad deaths down. More countries easing themselves out of lockdown. New research shows the virus can't stand summer temperatures. So many good signs, that you may be surprised shares are still languishing.
Hello, Share Spanners. A look at the daily trades for a recent recommendation of mine has recently shown quite a bit of profit-taking going on. But I’m hanging onto my shares because I think the upward action is far from over. And indeed Avacta (AVCT) is up by another 25% on its latest news...
Hello, Share Scudders. It’s worth an update on a successful recent tip on this venerable website. I refer to Avacta Group (AVCT). The share was well below 20p earlier this year. It’s up as I write to above 60p and in my humble opinion could have further to go...
Hello, Share Trundlers. A few days ago, I suggested a small medical pioneer might see a share rise because of its association with a substitute for human antibodies. This proved to be a correct assumption as the share has doubled since then.
Hello, Share Scramblers. My series of predictions of shares which may rise faster than others once the outbreak reaches its peak, today features Avacta (AVCT). This is one of my favourite biotech companies, though the share price hasn’t exactly sparkled over the years. So why might this share be of interest once it's safe to buy shares again?...
Hello, Share Breakers. It’s rare that I return to the same share shortly after a commendation. But for this company, I’m coming back a third time in fairly short order...
Hello, Share Speakers. If you’d acted on my Avacta (AVCT) commendation yesterday you’d be up by nearly 20% already. But I still think there’s a chance to make some more on this interesting share. What I didn’t have time to analyse yesterday was the latest trading update – which makes jolly reading...
Hello Share People. It’s all looking chipper for medical pioneer Avacta (AVCT). When Tom interviewed me fairly recently for his scintillating radio podcast, I gave this company the dubious award as my favourite penny share. And so far, luckily, I am proving right. The latest news is pretty exciting and, as I write, has propelled the share up by 15%...
Hello Share Makers. A company which I often return to because I think the potential is enormous is Avacta (AVCT). This is a Leeds-based medical pioneer which is developing artificial antibodies in the treatment of many serious conditions. The shares have just jumped on plans for a major study...
Hello Share Turners. There were loads of small companies hoping to attract your attention at the legendary Global Group UK Investor Show at the weekend. And it’s likely they wouldn't expose themselves to your criticism if they were not confident in their future. One of a phalanx of medical pioneers which takes a stand every year is Avacta (AVCT)...
Hello Share Twiddlers. There are few times I’m moved to revisit shares I’ve only recently commended. But occasionally the case for a company’s rosy prospects is so interesting that there’s justification for looking at the latest news. Avacta (AVCT) is a medical pioneer which I chose as a tip for 2019 on this wonderful website over Christmas. So much has happened for this Yorkshire firm lately that it’s hard to keep up with events...
Hello Share Charmers. So far, one of my pair of 2019 official tips on this magnificent website, Avacta (AVCT) has been charging ahead. But I think the success story could only just be starting. A trading update just released is firmly positive...
Hello Share Swashers. This may be the first time I’ve written three wall-to-wall articles about any company. But yet more positive news has broken from Avacta (AVCT), the medical pioneer. And I think it makes considering this interesting share even more compelling...
Hello, Share Pickers. Occasionally, limits of space curb doing justice to a share I’ve high hopes of. This was the case with Avacta (AVCT), which I dragged to your attention this week. Allow me to add two further aspects to my view of this thrilling share...
Hello, Share Bouncers. As the big shares continue to topple on the Brexit mess to end all messes, I still find myself in decent shape. And that’s because penny shares have a mind of their own, not usually affected by dodgy events of the day. Yes, I’m a big believer in the cheapos. My jumbo winner so far this week surged 32% in a day...
Hello, Share Dollies. One of those shares which never does much, despite what seems on paper to be a promising future is Avacta (AVCT). It's a maker of vet's stuff and also has a big interest in affimers, which are a substitute for antibodies for human medical research and diagnostics.
Hello, Share Planners. It’s been a while since I’ve revisited Avacta (AVCT), the firm looking at substitutes for antibodies in the great war against disease. But I’ve had two imperatives to look again at this interesting share. The first is that Avacta is also interested in treatment for animals and I had a sad journey to the vets today.
Hello, Share Squashers. As the usual boring summer for share shifters drags on, with hardly any exciting action on the Footsie front and most penny shares at a standstill, we all struggle to find spare value in any stocks at the moment. I’m keeping faith with most of my old faithfuls, even if some of them, like Photo-Me (PHTM) and Feedback (FDBK) seem to dither around without adding any value. This is possibly due to the time of year, as many traders are away for the school holidays.
Hello Share Takers. It’s ironical to call Avacta (AVCT) one of my favourite shares when it has only made a modest profit for me so far. And it’s taken a long time to do that. But it does seem to me that this medical pioneer is onto something. And a little talk with a couple of its big cheeses at last month’s stunning UK Investor Show strengthened that feeling.
Hello Share Screamers. We all know that investing in medical pioneers is a risky area. I’m still smarting from my losses with Advanced Oncotherapy (AVO) whose woes are under constant critical surveillance by Uncle Tom. But I believe that all share players have a bit of a duty to support selected medical pioneers. Think how much real suffering you will alleviate if the products being tried really do come off.
If the Prime Minister does a fraction of what she promised in her big speech this week, we can see shares soar like a stone from a ballista. But talk is cheap. However, as I’m not a cynical soul, there was the odd thing said which gave me hope - and I’m talking about my personal share portfolio. But I expect we hold a lot of sectors in common.
Hello Share Raisers. One share which I bracket among my stronger tips for 2017 is a company which provides diagnostic tools for vets. But its real potential, I believe, is in something called affimers. These are rather a mystery to me, but seem to be a substitute for antibodies. These, as we all know, fight disease.
Hello Share Twirlers. I’m indulging myself lately by featuring a few of my picks that are doing rather well at the moment. The last one we looked at was IQE, the electronics pioneer, which has been rattling ahead after a rather poor period, when I’m glad to say, I managed to hold my nerve. Now the share seems pretty perky. Today’s success story is Avacta (AVCT).
On the day of the big Brexit vote, the best shares for me to bring to your notice are the ones which staying in or coming should make no difference. One company which fits this bill and which has just made an exciting announcement is Avacta (AVCT). I have brought this life science outfit to your attention before. And so far not much has happened to the share price.
As you know, if we mention shares on here we cannot trade for a few days. That’s in case we get all enthusiastic over a company and then sell it during the supposed rush to buy, such as Avacta (AVCT).
As the big shares all decay, as I write, due to the Greek woes, the penny shares are, as usual, largely unaffected. And some of my large stable of cheapie are doing well enough to offset the disappointment in my Footsie collection.
A year ago, I had three beautiful cats. Now I have only one. In between, came some agonising trips to the vets to try and save two lives. It was not possible in the end, though of course my family did everything they could to postpone the inevitable.
Hello Share Shakers: Sadly, we've had to put to sleep our loving cat, Tumble. Aside from missing him badly, this set-back depresses me because I do not hold with euthanasia.
Hello Share Animals: I have a holding in a company called Avacta (AVCT). No they don't make films about blue people fighting for survival in 3D.
Hello Gang: There is a warm feeling to be had from investing in certain companies. Because you know that even if you lose a bit of money, you will still be doing some good.
Shares in Avacta (AVCT) are up 11% today 0.91p but the hot money is heading in and reckons that the shares could be heading for 2p before too long.
Search ShareProphets |
Recent Comments |